WallStSmart

AbbVie Inc (ABBV)vsPrecision BioSciences Inc (DTIL)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 146461% more annual revenue ($66.01B vs $45.04M). ABBV leads profitability with a 15.7% profit margin vs -85.6%. DTIL trades at a lower P/E of 30.3x. ABBV earns a higher WallStSmart Score of 77/100 (B+).

ABBV

Strong Buy

77

out of 100

Grade: B+

Growth: 6.7Profit: 9.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

DTIL

Avoid

26

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.3Quality: 5.5
Piotroski: 2/9Altman Z: -3.79
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-87.6%)

Margin of Safety

-87.6%

Fair Value

$157.25

Current Price

$294.64

$137.39 premium

UndervaluedFair: $157.25Overvalued
DTILUndervalued (+56.6%)

Margin of Safety

+56.6%

Fair Value

$9.38

Current Price

$7.28

$2.10 discount

UndervaluedFair: $9.38Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$520.47B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
36.6%10/10

Strong operational efficiency at 36.6%

EPS GrowthGrowth
2282.0%10/10

Earnings expanding 2282.0% YoY

Debt/EquityHealth
-17.6510/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.598/10

Growing faster than its price suggests

DTIL1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
37272.0%10/10

Revenue surging 37272.0% year-over-year

Areas to Watch

ABBV2 concerns · Avg: 2.0/10
P/E RatioValuation
50.6x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

DTIL4 concerns · Avg: 3.5/10
P/E RatioValuation
30.3x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$288.76M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 36.6%. Revenue growth of 10.3% demonstrates continued momentum.

Bull Case : DTIL

The strongest argument for DTIL centers on Revenue Growth. Revenue growth of 37272.0% demonstrates continued momentum.

Bear Case : ABBV

The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.6x leaves little room for execution misses.

Bear Case : DTIL

The primary concerns for DTIL are P/E Ratio, EPS Growth, Market Cap.

Key Dynamics to Monitor

ABBV profiles as a mature stock while DTIL is a hypergrowth play — different risk/reward profiles.

DTIL carries more volatility with a beta of 1.35 — expect wider price swings.

DTIL is growing revenue faster at 37272.0% — sustainability is the question.

ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (77/100 vs 26/100), backed by strong 15.7% margins and 10.3% revenue growth. DTIL offers better value entry with a 56.6% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Precision BioSciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.

Visit Website →

Want to dig deeper into these stocks?